BGIM
CORT icon

Brandywine Global Investment Management’s Corcept Therapeutics CORT Stock Holding History

Brandywine Global Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-248,066
Closed -$1.8M – 933
2016
Q4 		$1.8M Sell
248,066
-74,249
-23% -$582K 0.01% 574
2016
Q3 		$2.1M Sell
322,315
-7,297
-2% -$42.4K 0.01% 553
2016
Q2 		$1.8M Sell
329,612
-78,861
-19% -$410K 0.01% 563
2016
Q1 		$1.91M Buy
+408,473
New +$1.59M 0.01% 542

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Brandywine Global Investment Management's CORT Position: Q1 2017 in Review

Brandywine Global Investment Management sold out of Corcept Therapeutics (CORT) in Q1 2017, closing a stake of 248,066 shares — an estimated $1.8M sold.

Brandywine Global Investment Management first reported a position in CORT in Q1 2016 and held it in 4 quarters. The position peaked at $2.1M in Q3 2016. 135 funds tracked by Wall St. Rank hold CORT as of Q1 2017.

  • Brandywine Global Investment Management reported no remaining Corcept Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Brandywine Global Investment Management sold 248,066 Corcept Therapeutics shares in Q1 2017, an estimated $1.8M.
  • Brandywine Global Investment Management first reported a position in Corcept Therapeutics in Q1 2016 and held it in 4 quarters.
  • Brandywine Global Investment Management's Corcept Therapeutics position peaked at $2.1M in Q3 2016.
  • 135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2017.

Based on Brandywine Global Investment Management's 13F filing for Q1 2017, filed 15 May 2017.